Side-by-side comparison of AI visibility scores, market position, and capabilities
Embedded microcontroller leader (PIC, AVR, ARM MCUs) with $7.6B FY2024 revenue; deep inventory correction 2024-2025 after 46% revenue decline from peak; Atmel ($3.56B) and Microsemi ($8.35B) acquisitions.
Microchip Technology is a leading provider of microcontroller, digital signal controller, and analog semiconductor solutions for embedded control applications, founded in 1989 when Steve Sanghi led a management buyout of General Instrument's Microelectronics Division in Chandler, Arizona, where the company remains headquartered and trades on Nasdaq (MCHP). The company generated approximately $7.6 billion in net sales for fiscal year 2024 (ending March 31, 2024) under CEO Ganesh Moorthy, who succeeded Sanghi (who remains Executive Chair) in 2021. Microchip Technology has built one of the broadest microcontroller portfolios in the semiconductor industry through strategic acquisitions: the 2016 acquisition of Atmel ($3.56B) added AVR and SAM ARM-based microcontrollers, and the 2018 acquisition of Microsemi ($8.35B) added FPGAs, application-specific integrated circuits, timing products, and defense/aerospace-grade semiconductors that expanded Microchip's total addressable market substantially.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.